Literature DB >> 6493349

Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with ketanserin in the spontaneously hypertensive rat.

A Pettersson, B Persson, M Henning, T Hedner.   

Abstract

The effects of chronic oral treatment with the 5-hydroxytryptamine (serotonin) receptor blocking agent ketanserin (17 mg/100 g dry food) on blood pressure, heart weight, peripheral vascular reactivity, baroreceptor sensitivity, central cardiovascular reactivity and central catecholamine turnover were investigated in the spontaneously hypertensive rat. Blood pressure measurements were performed in conscious rats 24 h after insertion of catheters. After 6 weeks treatment basal blood pressure was reduced (16%) compared to control rats (given identical food, except for ketanserin). Both heart weight and body weight were reduced (both to 93% of control values) leaving heart weight/body weight ratio unchanged. Pressor responses to phenylephrine and depressor responses to isoprenaline (after pretreatment with reserpine and atropin) were not different while the blood pressure increase to 5-hydroxytryptamine was inhibited, indicating that after 6 weeks treatment the blood pressure reduction is not directly related to alpha-adrenoceptor blockade. Cardiovascular response to stress (jet air), baroreceptor sensitivity (bradycardia to phenylephrine) and central catecholamine synthesis rates (accumulation of 5-hydroxytryptophan and dihydroxyphenylalanine after synthesis inhibition) were unchanged supporting earlier evidence that central mechanisms probably do not contribute to the hypotensive effects of ketanserin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6493349     DOI: 10.1007/bf00504990

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  27 in total

1.  Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase.

Authors:  A Carlsson; J N Davis; W Kehr; M Lindqvist; C V Atack
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

2.  The effect of intense treatment with hypotensive drugs on structural design of the resistance vessels in spontaneously hypertensive rats.

Authors:  B Folkow; M Hallbäck; Y Lundgren; L Weiss
Journal:  Acta Physiol Scand       Date:  1971-10

3.  A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from the same tissue sample using a single column of strongly acidic cation exchange resin.

Authors:  C Atack; T Magnusson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1978-01

4.  Recordings of renal and splanchnic sympathetic nervous activity in normotensive and spontaneously hypertensive rats.

Authors:  P Thorén; S E Ricksten
Journal:  Clin Sci (Lond)       Date:  1979-12       Impact factor: 6.124

5.  Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors.

Authors:  J E Leysen; F Awouters; L Kennis; P M Laduron; J Vandenberk; P A Janssen
Journal:  Life Sci       Date:  1981-03-02       Impact factor: 5.037

6.  Renal function and sympathetic activity during mental stress in normotensive and spontaneously hypertensive rats.

Authors:  S Lundin; P Thorén
Journal:  Acta Physiol Scand       Date:  1982-05

7.  Consequence of social isolation on blood pressure, cardiovascular reactivity and design in spontaneously hypertensive rats.

Authors:  M Hallbäck
Journal:  Acta Physiol Scand       Date:  1975-04

8.  Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension.

Authors:  T Hedner; B Persson; G Berglund
Journal:  Clin Exp Hypertens A       Date:  1984

9.  Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.

Authors:  J M Van Nueten; P A Janssen; J Van Beek; R Xhonneux; T J Verbeuren; P M Vanhoutte
Journal:  J Pharmacol Exp Ther       Date:  1981-07       Impact factor: 4.030

10.  5-hydroxytryptamine and vascular disease.

Authors:  P M Vanhoutte
Journal:  Fed Proc       Date:  1983-02
View more
  8 in total

1.  Antihypertensive effect of long term ketanserin in elderly essential hypertensive patients. Assessment of left ventricular function at rest and during exercise.

Authors:  R A Sánchez; F Otero; A J Ramírez; O Degrossi; J Glenny; E J Marcó
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with irindalone in the spontaneously hypertensive rat.

Authors:  K Gradin; T Hedner; B Persson
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists.

Authors:  S Conolan; M J Quinn; D A Taylor
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

4.  Chronic 5-HT2 receptor blockade with ritanserin does not reduce blood pressure in the spontaneously hypertensive rat.

Authors:  K Gradin; A Pettersson; T Hedner; B Persson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

5.  Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.

Authors:  A Pettersson; K Gradin; T Hedner; B Persson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

6.  Pharmacokinetics of ketanserin in patients with cirrhosis.

Authors:  D Lebrec; A Hadengue; C Gaudin; J C Levron; B Fraitag; P Berthelot; J P Benhamou
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

7.  Inhibitory 5-hydroxytryptamine receptors involved in pressor effects obtained by stimulation of sympathetic outflow from spinal cord in pithed rats.

Authors:  A Morán; C Velasco; T Salvador; M L Martín; L San Román
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 8.  Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons.

Authors:  Thomas S Guillot; Gary W Miller
Journal:  Mol Neurobiol       Date:  2009-03-04       Impact factor: 5.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.